Epirubicin (hydrochloride)

Epirubicin (hydrochloride)

• CAS Number: 56390-09-1
• UNSPSC Description: Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase[1]. Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity[2].
• Target Antigen: Antibiotic; Apoptosis; DNA/RNA Synthesis; Topoisomerase
• Type: Reference compound
• Related Pathways: Anti-infection;Apoptosis;Cell Cycle/DNA Damage
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/epirubicin-hydrochloride.html
• Smiles: O=C(C1=C2C(O)=C3[C@@H](O[C@@]4([H])C[C@H](N)[C@@H](O)[C@H](C)O4)C[C@@](C(CO)=O)(O)CC3=C1O)C5=CC=CC(OC)=C5C2=O.Cl
• Molecular Weight: 579.98
• References & Citations: [1]Cersosimo RJ, et al. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986 Mar;4(3):425-39.|[2]Ozkan, A., et al. Epirubicin HCl toxicity in human-liver derived hepatoma G2 cells. Pol J Pharmacol, 2004. 56(4): p. 435-44.|[3]Bonadonna, G., et al. Drugs ten years later: epirubicin. Ann Oncol, 1993. 4(5): p. 359-69.|[4]Asanuma, F., et al. Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27. Folia Microbiol (Praha), 1998. 43(5): p. 473-4.|[5]Kashima H, et al. Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity. PLoS One. 2016 Jun 10;11(6):e0156643.Anal Chem. 2022 Oct 4;94(39):13623-13630.|bioRxiv. 2023 Jan 13.|Br J Cancer. 2024 Aug 22.|Cancer Res Treat. 2023 Jun 12.|Cell Death Discov. 2024 Jul 24;10(1):337.|Cell Mol Immunol. 2023 Jan;20(1):51-64.|Eur J Pharm Sci. 2024 Jul 21:106860.|Int J Cancer. 2024 Jul 15;155(2):324-338.|Int J Pharm. 2024 Aug 26:664:124622.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|Mol Cell. 2022 Feb 17;S1097-2765(22)00085-5.|Research Square Preprint. 2021 Nov.|Asia Pac J Clin Oncol. 2022 Dec 4.|bioRxiv. 2023 Apr 17.|Cell Prolif. 2021 Apr 1;e13038.|Exp Cell Res. 2020 Aug 1;393(1):112054.|Genome Med. 2024 Jan 12;16(1):11.|Genomics. 2021 Nov 26;S0888-7543(21)00410-9.|Int J Mol Sci. 2023, 24(1), 343.|J Biomed Inform. 2023 May 15;104383.|Mol Cancer. 2024 Jan 10;23(1):12.|Mol Pharm. 2019 Aug 5;16(8):3452-3459. |Oncol Lett. 2020 Apr. |Research Square Preprint. 2020 May.|Yonsei Med J. 2019 Sep;60(9):832-841.
• Shipping Conditions: Room Temperature